Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
393 results
  • Transdermal Delivery of Antipsychotics: Rationale and Current Status. [Journal Article]
    CNS Drugs 2019Abruzzo A, Cerchiara T, … Bigucci F
  • The aim of this article is to provide the rationale for the development of transdermal formulations of antipsychotics by highlighting their main advantages, starting with an overview of the antipsychotic formulations that are currently available on the market. Progress regarding transdermal antipsychotic formulations was investigated by performing a search of papers, patents and clinical trials p…
  • Asenapine: Pharmacological Aspects and Role in Psychiatric Disorders. [Journal Article]
    Psychiatr Danub 2019; 31(2):157-161Reyad AA, Mishriky R
  • Schizophrenia and bipolar disorders are serious psychiatric disorders with substantial health risks. Asenapine is a new second-generation antipsychotic, available as a sublingual tablet, approved in Europe for the treatment of moderate-to-severe manic episodes in adults, and in US for manic or mixed episodes of bipolar I disorder in adults and adolescents. In this review, we searched the availabl…
  • Safety considerations in the psychopharmacology of pediatric bipolar disorder. [Review]
    Expert Opin Drug Saf 2019; 18(9):777-794Sun AY, Woods S, … Stepanova E
  • Introduction: The standard of treatment of pediatric bipolar disorder (BPD) often requires life-long psychopharmacological management. Several pharmacological agents are approved by the US FDA for the treatment of pediatric BPD. However, each medication may cause adverse events (AEs). Provider awareness of AE profiles of common pharmacologic agents would serve to better inform patients and famili…
  • Asenapine for the treatment of bipolar disorder. [Journal Article]
    Expert Opin Pharmacother 2019; 20(11):1321-1330Marazziti D, Mucci F, … Dell'Osso L
  • Introduction: Bipolar I disorder (BDI) is amongst the most debilitating psychiatric conditions with a great impact on both patients and their families. A class of drugs commonly used in this condition is second-generation antipsychotics (SGAs) including asenapine, one of the latest to be introduced into the clinical practice worldwide to treat manic episodes in BDI. Areas covered: The aim of this…
New Search Next